Edges in Network
| Network | GSE5851_top8000 - GSE5851 - SiGN-BN NNSR |
| Network Description | Phase II exploratory pharmacogenomics study of cetuximab monotherapy in patients with advanced metastatic CRC |
| Node | LY96 |
| Upstream (Parents) |
|---|
| (<<) FCER1G → LY96 |
| (<<) HCLS1 → LY96 |
| (<<) CLEC2B → LY96 |
| (<<) TYROBP → LY96 |
| (<<) CD86 → LY96 |
| Downstream (Children) |
|---|
| LY96 → TAAR3 (>>) |
| LY96 → STAP1 (>>) |
| LY96 → LYL1 (>>) |
| LY96 → MMP23A///MMP23B (>>) |
| LY96 → PASK (>>) |
| LY96 → CXorf21 (>>) |
| LY96 → SPI1 (>>) |
| LY96 → SCARF1 (>>) |
| LY96 → PLTP (>>) |
| LY96 → AP1S2 (>>) |
| LY96 → LY86 (>>) |
| LY96 → PKD2L1 (>>) |
| LY96 → MARCH1 (>>) |
| LY96 → ADORA3 (>>) |
| LY96 → CHST15 (>>) |
| LY96 → DSE (>>) |
| LY96 → ZEB2 (>>) |
| LY96 → LPAR6 (>>) |
| LY96 → NPL (>>) |
| LY96 → CLEC2B (>>) |
| LY96 → C3AR1 (>>) |
| LY96 → RRAGD (>>) |
| LY96 → TYROBP (>>) |
| LY96 → GMFG (>>) |
| LY96 → C1orf54 (>>) |
| LY96 → SRGN (>>) |
| LY96 → ARHGDIB (>>) |
